Biogen Idec, Inc. (NASDAQ:BIIB)
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
NoblyNaive
(83.77)
Submitted: 4/30/2013 12:00:25 PM :
Start Price:
$218.78
BIIB Score:
-1.04
Excellent rides in March and April 2013: time for a threepeat!
High P/E; but Cramer's pitch on a small group of biotechs (REGN, BIIB, GILD, CELG) sold me.
April 17, 2013 update: Chart action still strong.
April 30, 2013 update: Chart action still strong.
Recs
elv1659
(31.18)
Submitted: 4/9/2013 12:24:42 PM :
Start Price:
$192.92
BIIB Score:
+11.02
Have a new pill for MS. Before patients had to take infusions. Much easier to administer and control disease.
Recs
Phuman2
(< 20)
Submitted: 4/9/2013 8:54:25 AM :
Start Price:
$194.51
BIIB Score:
+9.96
Steady growth and high profit margins
Recs
FutureMonkey
(84.94)
Submitted: 3/2/2013 2:57:41 PM :
Start Price:
$167.64
BIIB Score:
+25.32
Top 25 pick
Recs
42asdf
(48.23)
Submitted: 3/1/2013 4:50:40 PM :
Start Price:
$167.64
BIIB Score:
+25.32
has great growth, profit margins, and financial health. While it's p/e is fairly high (28.9), it is lower than the industry average (45.2).
Recs
NHWeston102
(76.09)
Submitted: 2/7/2013 11:47:24 AM :
Start Price:
$159.11
BIIB Score:
+31.33
If you can't develop a ground-breaker, buy one!! Tysabri will do BIIB good!
Recs
JorgeAura
(23.92)
Submitted: 2/2/2013 4:57:02 PM :
Start Price:
$156.15
BIIB Score:
-34.22
Nasdaq in maximums.
Recs
TMFHelical
(99.01)
Submitted: 11/13/2012 9:54:12 AM :
Start Price:
$139.82
BIIB Score:
+41.64
One of the leaders of an annual industry audit that looks at value creation in the biotech space.
http://caps.fool.com/Blogs/a-look-at-established-biotech/774287
Recs
portefeuille
(99.78)
Submitted: 12/15/2011 10:56:38 PM :
Start Price:
$102.70
BIIB Score:
+96.04
There are currently 270 BIIB shares in my "fund" with break-even of around 71.89 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Recs
macginty
(< 20)
Submitted: 7/30/2011 1:07:51 PM :
Start Price:
$105.91
BIIB Score:
+86.60
I feel that Tysabri's proven track-record over the past five years, as a prime treatment for multiple sclerosis, is providing real and worthwhile results for a very significant number of people, who must live with this otherwise 'incurable' disease.
Recs
TomFoolNC
(33.73)
Submitted: 5/28/2011 3:35:19 PM :
Start Price:
$93.96
BIIB Score:
+117.56
new mgt, cutting costs, refocusing investments
Recs
EclecticRecluse
(77.87)
Submitted: 5/5/2011 4:31:17 AM :
Start Price:
$95.84
BIIB Score:
+112.19
Upward Momentum
Recs
noguarantees
(86.18)
Submitted: 12/8/2010 3:12:51 AM :
Start Price:
$67.30
BIIB Score:
+201.33
BIIB is a good investment because it does not depend on reviews of brokers and experts such as Zacks. Take for example NKBP: Zacks gives it as "strong buy" for the past nine months, in fact NKBP continues to fall
Recs
gunterle
(65.54)
Submitted: 10/20/2010 11:04:02 AM :
Start Price:
$67.41
BIIB Score:
+208.25
Trendspotter
Recs
syljtffreedom
(80.72)
Submitted: 10/7/2010 10:52:55 PM :
Start Price:
$57.05
BIIB Score:
+253.78
takeover target!
Recs
Bigdog2020
(84.78)
Submitted: 7/23/2010 3:04:48 PM :
Start Price:
$53.66
BIIB Score:
+271.57
Great pipeline - 5 filings over next few years. Nimble size and new leadership will further focus this company and drive continued earnings growth.
Recs
gsabc
(90.10)
Submitted: 7/1/2010 3:49:38 PM :
Start Price:
$46.70
BIIB Score:
+323.57
With the house in order, the pipeline chugging along and Icahn placated (one hopes), this should be a good long-term gainer.
Recs
elliotyoung
(< 20)
Submitted: 5/2/2010 12:53:39 AM :
Start Price:
$52.70
BIIB Score:
+289.58
Buy. Good momentum and PEG.
Recs
watchit2
(< 20)
Submitted: 2/17/2010 12:46:02 AM :
Start Price:
$55.31
BIIB Score:
-258.75
Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri and Avonex will go down. Even the new drug, Fampridine will struggle.
http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5
Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS.
http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspx
Or, www.ctv.ca Search “CCSVI”
And www.ccsvivictory.club.officelive.com check “conflicts of interest” tab
Recs
jahjimhall
(< 20)
Submitted: 2/11/2010 4:59:10 PM :
Start Price:
$55.08
BIIB Score:
-255.82
Cutting back on R&D to help short term earnings at the expense of long term earnings (Ichann infleuence). Not a good move with competitors moving into same space
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 88 : 1 2 3 4 5 Next »